NZ540043A - Isolated or recombinant Interferon-alpha polypeptides and conjugates - Google Patents

Isolated or recombinant Interferon-alpha polypeptides and conjugates

Info

Publication number
NZ540043A
NZ540043A NZ540043A NZ54004303A NZ540043A NZ 540043 A NZ540043 A NZ 540043A NZ 540043 A NZ540043 A NZ 540043A NZ 54004303 A NZ54004303 A NZ 54004303A NZ 540043 A NZ540043 A NZ 540043A
Authority
NZ
New Zealand
Prior art keywords
seq
polypeptide
amino acid
sequence
alpha
Prior art date
Application number
NZ540043A
Other languages
English (en)
Inventor
Phillip A Patten
Sridhar Govindarajan
Sridhar Viswanathan
Torben Lauesgaard Nissen
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Publication of NZ540043A publication Critical patent/NZ540043A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ540043A 2002-11-18 2003-11-17 Isolated or recombinant Interferon-alpha polypeptides and conjugates NZ540043A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42761202P 2002-11-18 2002-11-18
US50256003P 2003-09-12 2003-09-12
PCT/US2003/036682 WO2004046365A2 (en) 2002-11-18 2003-11-17 Interferon-alpha polypeptides and conjugates

Publications (1)

Publication Number Publication Date
NZ540043A true NZ540043A (en) 2007-11-30

Family

ID=32329174

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ540043A NZ540043A (en) 2002-11-18 2003-11-17 Isolated or recombinant Interferon-alpha polypeptides and conjugates

Country Status (13)

Country Link
US (1) US20040219131A1 (OSRAM)
EP (1) EP1565205A4 (OSRAM)
JP (1) JP2006506097A (OSRAM)
KR (1) KR20050086498A (OSRAM)
AU (1) AU2003297285A1 (OSRAM)
BR (1) BR0316324A (OSRAM)
CA (1) CA2504267A1 (OSRAM)
IL (1) IL168049A0 (OSRAM)
MX (1) MXPA05005263A (OSRAM)
NO (1) NO20052363L (OSRAM)
NZ (1) NZ540043A (OSRAM)
RU (1) RU2005118998A (OSRAM)
WO (1) WO2004046365A2 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040715A2 (en) 1999-01-05 2000-07-13 Trustees Of Boston University Improved nucleic acid cloning
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
CN102319437B (zh) 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
MXPA05006945A (es) * 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor.
WO2004076474A2 (en) * 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
CA2553528C (en) 2004-01-21 2012-12-04 Nektar Therapeutics Al, Corporation Method of preparing propionic acid-terminated polymers
BRPI0511196A (pt) 2004-05-19 2007-12-04 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição
CA2572751A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
JP2008519602A (ja) 2004-11-11 2008-06-12 モジュラー ジェネティクス， インコーポレイテッド 多様性を生じるためのラダーアセンブリおよびシステム
US9931413B2 (en) * 2005-04-06 2018-04-03 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
EP3214095B1 (en) * 2005-05-12 2019-12-11 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
US7619067B2 (en) 2005-05-18 2009-11-17 Maxygen, Inc. Evolved interferon-alpha polypeptides
JP2010504909A (ja) 2006-09-14 2010-02-18 メドジェニクス・メディカル・イスラエル・リミテッド 長期持続性の医薬製剤
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
CN1970572A (zh) * 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
KR101591887B1 (ko) 2010-06-15 2016-02-04 메드제닉스 메디칼 이스라엘 리미티드 장기 지속형 약물 제형
US20130225789A1 (en) * 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
AU2022328512A1 (en) * 2021-08-18 2024-03-28 Remd Biotherapeutics, Inc. Novel interferon variants and bifunctional fusion molecules thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4801685A (en) * 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
ATE78262T1 (de) * 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CN1361793A (zh) * 1999-05-19 2002-07-31 利思进药品公司 干扰素－α蛋白作为Fc融合蛋白的表达和运输
CA2385045A1 (en) * 1999-10-07 2001-04-12 Maxygen, Inc. Ifn-alpha homologues
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
AU2002223350A1 (en) * 2000-12-01 2002-06-11 Eleanor N. Fish Cytokine receptor binding peptides
DE60307881T2 (de) * 2002-11-15 2007-03-08 F. Hoffmann-La Roche Ag Positionelle isomeren von pegyliertem interferon alpha 2a

Also Published As

Publication number Publication date
WO2004046365A3 (en) 2004-09-02
US20040219131A1 (en) 2004-11-04
AU2003297285A1 (en) 2004-06-15
EP1565205A2 (en) 2005-08-24
CA2504267A1 (en) 2004-06-03
IL168049A0 (en) 2009-02-11
MXPA05005263A (es) 2005-07-25
WO2004046365A2 (en) 2004-06-03
BR0316324A (pt) 2005-09-27
NO20052363L (no) 2005-08-08
EP1565205A4 (en) 2006-07-05
JP2006506097A (ja) 2006-02-23
NO20052363D0 (no) 2005-05-12
RU2005118998A (ru) 2006-01-27
KR20050086498A (ko) 2005-08-30

Similar Documents

Publication Publication Date Title
US7314613B2 (en) Interferon-alpha polypeptides and conjugates
US7537755B2 (en) Interferon-alpha polypeptides and conjugates
US20040219131A1 (en) Interferon-alpha polypeptides and conjugates
US7619067B2 (en) Evolved interferon-alpha polypeptides
ZA200503782B (en) Interferon-alpha polypeptides and conjugates

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed